Analysts at Roth Capital initiated coverage on Alcobra Pharma ADHD with a Buy rating.
The target price for Alcobra Pharma is set to $40.
Alcobra Pharma shares have surged 24.43% over the past 52 weeks, while the S&P 500 index has gained 12.93% in the same period.
Alcobra Pharma's shares dropped 3.33% to close at $17.42 yesterday.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in